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Abstract The 3¢ untranslated regions (3¢ UTRs) of
human protein-coding genes play a pivotal role in the
regulation of mRNA 3¢ end formation, stability/deg-
radation, nuclear export, subcellular localisation and
translation, and hence are particularly rich in cis-acting
regulatory elements. One recent addition to the
already large repertoire of known cis-acting regulatory
elements are the microRNA (miRNA) target sites that
are present in the 3¢ UTRs of many human genes.
miRNAs post-transcriptionally down-regulate gene
expression by binding to complementary sequences on
their cognate target mRNAs, thereby inducing either
mRNA degradation or translational repression. To
date, only one disease-associated 3¢ UTR variant (in
the SLITRK1 gene) has been reported to occur within
a bona fide miRNA binding site. By means of sequence
complementarity, we have performed the first system-
atic search for potential miRNA-target site mutations
within a set of 79 known disease-associated 3¢ UTR
variants. Since no variants were found that either dis-
rupted or created binding sites for known human
miRNAs, we surmise that miRNA-target site muta-
tions are not likely to represent a frequent cause of
human genetic disease.
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Abbreviations
LAS Left arm of the ‘spacer’ sequence between
the upstream core polyadenylation signal
and the pre-mRNA cleavage site
miRNA MicroRNA
UCPAS Upstream core polyadenylation signal
USS Upstream sequence between the
translational termination codon and the
UCPAS
3¢ UTR 3¢ Untranslated region
Introduction
The 3¢ untranslated regions (3¢ UTRs) of human
protein-coding genes play a pivotal role in the regula-
tion of mRNA 3¢ end formation, stability/degradation,
nuclear export, subcellular localisation and translation
and are thus particularly rich in cis-acting regulatory
elements (for recent reviews, see Chen et al. 2006a, b).
One recent addition to the already large repertoire of
cis-acting regulatory elements are the microRNA
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(miRNA) target sites that are present in the 3¢ UTRs
of many human genes (e.g. John et al. 2004; Kiriakidou
et al. 2004; Grun et al. 2005; Krek et al. 2005; Lewis
et al. 2005; Robins and Press 2005; Xie et al. 2005).
miRNAs are an abundant class of small (~22 nucleo-
tide) non-coding RNAs. Upon binding to their cognate
targets, they post-transcriptionally down-regulate gene
expression by inducing either mRNA degradation or
translational repression (for recent reviews, see Pillai
2005; Kim and Nam 2006; Valencia-Sanchez et al.
2006). To date, at least 800 distinct human miRNAs
(~3% of the total number of human genes) have been
identified (Bentwich et al. 2005) but many more
probably still remain to be discovered. These miRNAs
are each likely to be responsible for repressing the
expression of a large number of different target genes
(Lim et al. 2005).
The importance of miRNAs in gene regulation and
their potential significance in both cancer biology and
gene evolution (Farh et al. 2005; Lim et al. 2005; Zhang
et al. 2006) suggests that mutations in miRNA-target
sites might well also be important in the aetiology of
human inherited disease. Indeed, one such lesion has
recently been reported: a G ﬁ A transition (absent in
4,296 control chromosomes), which replaces a G:U
wobble base-pair with an A:U Watson–Crick pairing in
a binding site for human miRNA hsa-miR-189 within
the 3¢ UTR of the Slit and Trk-like 1 gene (SLITRK1;
MIM# 609678), was identified in two unrelated patients
with Tourette’s syndrome and obsessive-compulsive
symptoms (Abelson et al. 2005; Fig. 1). In vitro func-
tional analysis demonstrated that, in the presence of
hsa-miR-189, the mutant allele gave rise to increased
repression of the reporter gene as compared with the
wild-type allele.
In this study, we have made a first attempt to iden-
tify further potential miRNA-binding site mutations by
systematically screening previously reported disease-
associated 3¢ UTR variants.
Materials and methods
Data source
Of the previously collected 3¢ UTR variants, only those
that occurred within the sub-region known as the USS
(upstream sequence between the translational termi-
nation codon and the UCPAS, upstream core poly-
adenylation signal) were included for analysis (Chen
et al. 2006a, b). The variants that occurred within the
UCPAS and LAS (left arm of the ‘spacer’ sequence
between the UCPAS and the pre-mRNA cleavage site)
of the 3¢ UTR were excluded from evaluation for two
reasons: (i) their number is very limited and (ii) almost
all of these variants are explicable in terms of well-
established pathological mechanisms.
Of the 83 previously identified USS variants, four
isolated examples (i.e. Group 5 in Chen et al. (2006b))
were excluded owing to their complex nature. Thus, a
total of 79 USS variants (viz. Groups 1–4 in Chen et al.
(2006b)) were studied here.
Search for miRNA-binding sites spanning the sites
of USS variants
Sequence spanning the 79 collated USS variants was
searched for all known miRNA binding sites with miR-
Base software (http://microrna.sanger.ac.uk/sequences/
search.shtml; Griffiths-Jones et al. 2006) using default
parameters. For each variant, both the wild-type 3¢UTR
Fig. 1 Complementarity of several pairs of wild-type and variant
alleles with different miRNAs. Watson–Crick base-pairs are
depicted by bars. Gaps (indicated by asterisks) were introduced
so as to maximise complementarity in the cases of HBB and
THPO. The single nucleotide substitutions that distinguish the
variant alleles from the wild-type alleles are highlighted in bold
and grey. The only known pathological mutation in an miRNA-
target site, a G > A transition in the 3¢ UTR of the SLITRK1
gene in two patients with Tourette’s syndrome (Abelson et al.
2005), is included for the sake of comparison
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sequence and its mutated counterpart, each of total
length ~50 bp flanking the site of mutation, were
screened for the presence of miRNA binding sites, with
all possible 25 bp fragments within these flanking se-
quences being examined sequentially.
Results and discussion
General considerations about miRNA target
prediction
Whereas miRNAs have emerged as a new class of
regulatory gene (reviewed in Alvarez-Garcia and
Miska 2005; Yang et al. 2005; Kim and Nam 2006;
Krutzfeldt et al. 2006), miRNA-target sites within the
3¢ UTRs of human protein-coding genes constitute a
new class of cis-acting regulatory elements. Although
the mechanism underlying miRNA-target site interac-
tions still remains to be elucidated, it is clear that the
initiation of target site recognition often relies on short
stretches (6–8 bp) of perfect (and consecutive)
Watson–Crick miRNA-mRNA complementarity; this
perfect match is typically located at the 5¢ end of the
miRNA (termed the ‘seed’ site; Lewis et al. 2003, 2005;
Bentwich 2005; Brennecke et al. 2005; Rajewsky 2006).
Secondary structure has also been employed to
predict miRNA targets in two recent studies (Robins
et al. 2005; Zhao et al. 2005). However, as opined by
Rajewsky (2006), ‘‘it is not yet clear if the proposed
algorithms help to improve specificity or sensitivity of
algorithms that do not take into account 3¢ UTR sec-
ondary structure’’. Rajewsky also raised two problems
related to secondary structure prediction viz. the
unreliability of the mfold program (Zuker et al. 2003)
in cases where input length exceeds a given limit, and
the question of whether the predicted secondary
structure can be extrapolated to the in vivo situation.
In this regard, it is pertinent to note that using ‘local’
rather than ‘global’ secondary structure prediction, we
identified consistent patterns of secondary structural
change that potentiated the discrimination of func-
tional USS variants from their non-functional coun-
terparts (Chen et al. 2006b). We should however
emphasise that these predictions were made in the
context of interactions between mRNAs and their
cognate trans-acting proteins. Trans-acting RNA
molecules may well bind/influence a given mRNA
secondary structure in rather different ways than
trans-acting proteins. Further, the free energy of the
miRNA/mRNA duplex, which has often been evalu-
ated alongside sequence complementarity, has been
found to be a poor predictor of miRNA-target sites
(Rajewsky and Socci 2004; Rajewsky 2006).
Consequently, in seeking potential miRNA-target
site mutations amongst the 79 known 3¢ UTR variants
(Chen et al. 2006a, b), we relied entirely upon the
criterion of sequence complementarity at the ‘seed’
site. Under stringent conditions viz. the requirement of
at least a 7-nt consecutive match to the first eight
nucleotides at the 5¢ end of the miRNA (Bentwich
2005; Brennecke et al. 2005), none of the analysed USS
variants were found to disrupt or create binding sites
for known human miRNAs. However, under more
relaxed conditions, viz. the requirement of at least a
5-nt consecutive match to the ‘seed’ region of the
miRNA, four such cases were found (Fig. 1). The
observed E-values for these ‘hits’ were found to be >1
but <10 (default parameters); hence the formal prob-
abilities of finding these alignments by chance alone
were relatively high (HBB, 0.9257; DPYSL2, 0.2289;
THPO, 0.7759; PTGS2, 0.8891). The utility of such a
statistical analysis should probably not be overstated
since, in the case of the Tourette’s syndrome-associ-
ated mutation located within the hsa-miR-189-binding
site in the 3¢ UTR of the SLITRK1 gene (Abelson
et al. 2005), we calculate that the corresponding
P-value for finding this sequence similarity by chance
alone is 0.8647.
The secondary structural changes associated with these
four variants have been previously predicted by Chen
et al. (2006b). Although one (DPYSL2), which also had
the lowest P-value (0.2289) of the four candidate muta-
tions, was predicted to generate a type 1 secondary
structural change with unknown functional significance,
the remaining three [as well as the G ﬁ A mutation in
the SLITRK1 gene (Abelson et al. 2005)] were predicted
to generate a pattern I secondary structural change (Chen
et al. 2006b). It is nevertheless impossible to draw any firm
conclusions at this stage. The four variants in question
(Fig. 1) will therefore now be discussed individually in the
context of their putative disease-associations and poten-
tial biological significance.
HBB: Predicted functional consequence
inconsistent with the presumed causative role
The C>G mutation, 6 nucleotides downstream of the
translational termination codon of the HBB gene
(MIM# 141900; encoding b-globin), was reported in
b-thalassaemia intermedia patients (Jankovic et al.
1991; Maragoudaki et al. 1998). The mutant G allele
displays decreased complementarity to miRNA hsa-
miR-214 as compared with the wild-type C allele
Genomic Med (2007) 1:29–33 31
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(Fig. 1). Thus, it might be predicted that the mRNA
product of the HBB G allele would be less subject to
miRNA-mediated gene repression. Were this to be
true, the HBB G variant allele might be expected to be
associated with increased expression of the gene as
compared with the wild-type C allele; this would
however be inconsistent with the variant’s putative role
in causing b-thalassaemia intermedia. This notwith-
standing, it still remains possible that the variant G
allele constitutes a miRNA target mutation. However,
in this case, any ensuing functional consequences
would have been concealed by a concomitant effect on
mRNA stability, an effect already demonstrated by in
vitro functional analysis (Sgourou et al. 2002).
DPYSL2: Predicted functional consequence
partially consistent with the presumed causative
role
The 2236T>C polymorphism in the 3¢ UTR of the
dihydropyrimidinase-like 2 gene (DPYSL2; MIM#
602463) was reported to reduce the susceptibility to
schizophrenia in a Japanese patient sample (Nakata
et al. 2003). Based upon the observation that the
expression of DPYSL2 is significantly decreased in the
frontal cortex of people with schizophrenia and affec-
tive disorder (Johnston-Wilson et al. 2000), were the C
allele to be ‘disease-protective’, it might reasonably be
expected to give rise to increased expression of the
gene. This would contrast with the prediction that the
C allele should be more subject to translational
repression by hsa-miR-302b than the T allele (Fig. 1).
However, in a North American Caucasian population,
the C allele has been reported to increase susceptibility
to schizophrenia (Hong et al. 2005). If this later finding
were not simply spurious, the predicted functional
consequence of the T>C polymorphism would be
consistent with its presumed causative role.
THPO and PTGS2: Predicted functional
consequences consistent with presumed causative
roles
If the rs6141(+24)G>A polymorphism in the THPO
gene were indeed to be associated with a low platelet
count (Garner et al. 2005), it should result in the
increased expression of the gene because circulating
plasma levels of THPO are generally inversely corre-
lated with platelet levels (Garner et al. 2005 and ref-
erences therein). If the 9850A>G polymorphism in the
PTGS2 gene were indeed to confer colorectal cancer
risk (Cox et al. 2004), it should also lead to over-
expression of the gene (see Campa et al. 2004 for
relevant information). The reduced complementarity
of the THPO A variant allele to hsa-miR-431 and of
the PTGS2 G variant allele to hsa-miR-132, as com-
pared with their respective wild-type alleles (Fig. 1), is
therefore consistent with such functional conse-
quences.
Conclusions
We have taken a set of known disease-associated 3¢
UTR variants and performed the first systematic search
for potential miRNA-target site mutations. Under
fairly stringent conditions that required at least a 7-nt
consecutive match to the first eight nucleotides at the 5¢
end of the miRNA (Bentwich 2005; Brennecke et al.
2005), no variants were found that either disrupted or
created binding sites for known human miRNAs. The 3¢
UTR of the HBB gene, which displays a 6-nt consecu-
tive match with the seed region of hsa-miR-214, could
potentially serve as a functional miRNA target. How-
ever, not only does the C>G mutation not occur within
the seed region, but its predicted functional conse-
quence is also inconsistent with its presumed causative
role, making it unlikely to be biologically significant in
the context of miRNA-target interactions. As for the
remaining three variants, it appears unlikely that
5-mers would be sufficient to serve as seeds for the
initiation of miRNA-target site recognition. In sum-
mary, our analysis has suggested that miRNA-target
site mutations are not a frequent cause of human
genetic disease.
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